Figure 1.

LMO2 has prognostic utility in different therapeutic eras independently of DLBCL subtype. (A) LMO2 expression was the best predictor of survival within a 6-gene model in patients treated with CHOP (n = 66)²⁰ or R-CHOP (n = 132).¹⁹ Univariate z-scores from Cox regression reflect the magnitude of association for each gene with survival; positive and negative z-scores reflect association between higher expression of a given gene with adverse and favorable risk, respectively. Dotted lines correspond to P = .05. (B) LMO2 overexpression is associated with GCB subtype (P < .0001), yet can stratify outcomes even within this subtype (supplemental Table 1 and supplemental Figure 1D).